Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that three German-based companies have selected ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) into their respective corporate health programs.
https://finance.yahoo.com/news/mainz-biomed-expands-corporate-health-070100525.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.